Home Alzheimer’s Disease FDA Approves Olaparib for HRR Gene-Mutated mCRPC

FDA Approves Olaparib for HRR Gene-Mutated mCRPC

The FDA has approved olaparib (Lynparza) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone (Zytiga), according to AstraZeneca and Merck, the joint developers of the agent.

The FDA recommended a dose of 300 mg of olaparib, taken orally twice daily, with or without food. 

“Prostate cancer has lagged behind other solid tumors in the era of precision medicine,” Maha Hussain, MD, one of the principle investigators of the trial and deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, said in a press release. “I am thrilled by the approval of (olaparib), which now brings a molecularly targeted…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments